Overview

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.
Details
Lead Sponsor:
Sir Charles Gairdner Hospital
Treatments:
Darbepoetin alfa
Hematinics